In light of draft guidance issued by the U.S. Food and Drug Administration (FDA) regarding the communication of scientific information of unapproved uses (SIUU) of approved medical medical products, EVERSANA continues to assess the potential risk and opportunity for more informative conversations between pharmaceutical manufacturer representatives and healthcare providers (HCPs) regarding the care of individual patients.
In this new article by Anne Marie Robertson and Tim Lewis, discover top-level considerations for SIUU guidance across various channels and how it may impact manufacturers and their field force strategies.
Some topics discussed throughout the article include:
- Context of the FDA guidance
- Field usage
- Guidance history
- Considerations for SIUU communications across media, website and social media
- Implications on congresses and commercial sales teams
While there is not yet consensus on the draft guidance, there is an opportunity to incorporate these considerations into your field activities and strategies today. EVERSANA can help organizations navigate these uncertainties. Explore EVERSANA’s oncology and hematology market insights and the benefits of our innovative commercialization model.
Author
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…
Tim has served as a strategic lead to healthcare companies for more than 25 years in advertising, marketing, and finance roles in agency and client settings. His work spans pre-clinical to sunset strategies and from brand infrastructure to digital roadmaps. He has helped stand up clinical trial…